RE:RE:RE:SA REPORTS FOURTH Q RESULTSJkj, kelsee just reposted the excellent list of questions that people on Agora has developed and sent to RVX.
I will be very pleased if the RVX and Zenith webcasts seriously address each of these questions with a concerted effort. That would be a clear signal of at least some respect for retail shareholders and will substantially reduce doubts and concerns.
At the end of the day science is science. It might be possible to accelerate dosing of a trial but at the end of the day each treated patient requires a certain amount of time to be assessed...that's just science. Things like FDA approvals take tremendous time. However, with Trumps new appointment this could change fast??? There is alot of exciting stuff happening...orphan trials, renal, etc. I hope we get concrete info on this stuff.
So we'll see what happens tomorrow. There were 2 events that happened that still make me curious;
- The share price and volume run up starting back on Sept 13, 2016.
- The restructuring of the Zenith Capital royalty preferred share.
I wonder if tomorrow will give us the answer. We'll know soon.
Cheers
Toinv